Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Actinium Pharmaceuticals Stock Down 4.9 % Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a ...

At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...